Top Industry Leaders in the Diabetic Nephropathy Market
Latest Diabetic Nephropathy Companies Updates
AstraZeneca: The pharmaceutical giant partnered with Verve Therapeutics to develop gene therapy candidates for diabetic kidney disease, showcasing their commitment to exploring innovative treatment options.
Boehringer Ingelheim: Announced positive Phase 2b trial results for their investigational drug naptumomab abdecatum, demonstrating its potential to slow kidney function decline in patients with diabetic nephropathy.
Reata Pharmaceuticals: Achieved a key milestone with the FDA granting Fast Track designation to their lead candidate bardoxolone methyl, signifying the agency's recognition of the drug's potential to address a significant unmet medical need in diabetic nephropathy.
List of Diabetic Nephropathy Key companies in the market:
-
Novartis AG (Switzerland)
-
Merck & Co., Inc. (US)
-
Abbott Laboratories (US)
-
Sanofi (France)
-
Eli Lilly and Company (US)
-
Reata Pharmaceuticals, Inc. (US)
-
Bayer AG (Germany)
-
AbbVie, Inc. (US)
-
AstraZeneca (UK)